Biogen Idec, Inc. (BIIB)
$45.76
1.37 (+3.09%)
| CAPS Rating |
|
|---|---|
| Open | $44.44 |
| Previous Close | $44.39 |
| Daily Range | $44.11 - $46.47 |
| 52-Week Range | $37.21 - $55.34 |
| Market Cap | $13.23B |
| P/E Ratio | 14.80 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 8,626,797 |
| Average Daily Volume | 3,690,000 |
BIIB
VS S&P 500 (SPY)
How do you think BIIB will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
BIIB Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
BIIB News and Commentary
- 4-Star Stocks on the Upswing – The Motley Fool
- Nice Quarter, Teva. What Will You Buy Next? – The Motley Fool
- 10 Stocks Shaking the Market – The Motley Fool
- Finally Convinced? Benlysta Works! – The Motley Fool
- Earnings? Yawn. Trial Data? Moving! – The Motley Fool
- Don't Make This Humongous Life-Wrecking Error – The Motley Fool
- 3 Stocks in a Tailspin – The Motley Fool
- UPDATE 1-EU agency reports 24th case of Tysabri infection – Reuters
- For Tysabri, 23 Is 10 Too Many – The Motley Fool
- The S&P 500's Biggest Movers – The Motley Fool
- 4-Star Stocks Poised to Pop: Elan – The Motley Fool
- CNBC on Biogen IDEC, Inc. – Ockham-RazorWire
- UPDATE 1-Biogen, Elan shares plummet on new Tysabri review – Reuters
- What Are You Waiting For? – The Motley Fool
- Elan's Headed in the Right Direction – The Motley Fool
- All Tysabri, All the Time – The Motley Fool
- UPDATE 1-Biogen third-quarter profit tops expectations – Reuters
- Do You Have the Guts to Buy? – The Motley Fool
- Little Discord on Acorda Drug – The Motley Fool
- 1-Star Stocks Poised to Plunge: Human Genome Sciences? – The Motley Fool
RSS Headlines
Fool UK
